Testosterone and erectile dysfunction

Journal of Andrology

Volumn 29, Issue 6, 2008, Pages 593-604

  Yassin, Aksam A ^a,c   Saad, Farid ^b  

^a Segeberger Kliniken   (Germany)

^b BAYER PHARMA AG   (Germany)

^c NONE   (Germany)

Author keywords

PDE 5 inhibitors; Penis

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; GLUCOSE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; INSULIN; LEUPRORELIN; LUTEINIZING HORMONE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; VARDENAFIL;

ABNORMAL VISION; AGE; ANDROGEN THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE ASSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; IMPOTENCE; INSULIN RESISTANCE; LIBIDO; METABOLIC SYNDROME X; MONOTHERAPY; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORCHIECTOMY; PATHOGENESIS; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RHINITIS; RISK FACTOR; SEXUAL FUNCTION; SIDE EFFECT; SMOKING; SMOOTH MUSCLE RELAXATION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VEIN OCCLUSION;

AGING; ANIMALS; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; TESTOSTERONE;

EID: 56249147487     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.004630     Document Type: Review

References (145)

1. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity and insulin resistance. J Clin Endocrinol Metab. 2002;87:4522-4527.
2. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl. 2006;27:335-347.
3. Aliaev IuG, Vinarov AZ, Akhvlediani ND. Therapeutic efficacy of a course administration of vardenafil - inhibitor of phosphodiesterase-5 - in erectile dysfunction [in Russianl. Urogiia. 2007;1:45-46.
4. American Society of Andrology. Testosterone replacement therapy for male aging: SAS position statement. J Androl. 2006;27:133-134.
5. Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of suprapraphysiological levels of testosterone in normal men. Thromb Haemost. l995;74:693-697.
6. Armagan A, Kim NN, Goldstein I, Traish AM. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl. 2006;27(4): 517-526.
7. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf). 2000;53:517-522.
8. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilatation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol. 2003;58:632-638.
9. Baba K, Yajima M, Carrier S, Akkus E, Reman J, Nunes L, Lue TF, Iwamoto T. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology. 2000a;56:533-538.
10. Baba K, Yajima M, Carrier S, Morgan DM, Nunes L, Lue TF, Iwamoto T. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int. 2000b;85:953-958.
11. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behaviour in normal young men. J Clin Endocrinol Metab. 1994;78(3):711-716.
12. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann of Intern Med. 1992;117:807-811.
13. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older men with diabetes mellitus. American Journal of Epidemiology. 1990;132:895-901.
14. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D. Sex hormone changes in morbidly obese patients after vertical banded gastroplasty. Eur Surg Res. 1998;30: 43-47.
15. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181.
16. Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz PJ. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction. Methods Mol Biol. 2004;279:173-185.
17. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Artherioscler Thromb Vasc Biol. 2003;23:168-175.
18. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1-7.
19. Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR, Galmarini M, Bhasin S. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril. 1993;59(5): 1118-1123.
20. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol. 1997;157:320-324.
21. Burnett AL. Novel nitric oxide signalling mechanisms regulate the erectile response. Int J Impotence Res. 2004;16:15-19.
22. Carani C, Granata AR, Bancroft J, Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology. 1995;20:743-753.
23. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL, Chang TS. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995; 63(5):1101-1107.
24. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, Kim IJ, Pomerantz K, Park C, Kimm KC, Choi DS. Elevated homocysteine as a risk factor for the development of diabetes in women with a previous history of gestational diabetes mellitus: a 4-year prospective study. Diabetes Care. 2005;28:2750-2755.
25. Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM, Collins P, Chatterjee K. Testosterone induces dilation of canine coronary conductance and fesistance arteries in vivo. Circulation. 1996;94: 2614-2619.
26. Cohen P. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52:49-51.
27. Corbin JD, Francis SH. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl. 2003;24(6):S38-S41.
28. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Manansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006;50:595-604.
29. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71-77.
30. DeBusk RF. Erectile dysfunction therapy in special populations and applications: coronary artery disease. Am J Cardiol. 2005;96: 62M-66M.
31. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol and Metab. 2004;89:5462-5468.
32. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci. 2003;104:195-201.
33. Edwards E, Hamilton J, Duntley S. Testosterone propionate as a therapeutic agent in patients with organic disease of peripheral vessels. N Engl J Med. 1939;220:865-869.
34. Ellis WJ, Grayhack JT. Sexual function in aging males after orchiectomy and estrogen therapy. J Urol. 1963;89:895-898.
35. Esposito K, Ciotola M, Giugliano D. Inflammation Warms Up the Metabolic Syndrome. Arterio Thromb Vasc Biol. 2005;25:e143.
36. Foresta C, Coretta N, Rosatto M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol. 2004;171:2358-2362.
37. Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod. 1995;53(6):1365-1372.
38. Gooren L. The role of testosterone in erectile function and dysfunction. J Men's Health Gender. 2006;3(3):292-298.
39. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone therapy alone failed? J Urol. 2003;173:530-532.
40. Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol. 1995;153:650-652.
41. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22:793-797.
42. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J of Epidemiol. 1996;143:889-897.
43. Haffner SM, Valdez RA, Stern MP, Katz MS. Obesity, body fat distribution and sex hormones in men. Int J Obes. 1993;17: 643-649.
44. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232-1240.
45. Harle L, Basaria S, Dobbs AS. Nebido: a long-lasting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother. 2005;6:1751-1759.
46. Harman SM, Metter EJ, Tobin JD, Pearson J. Baltimore. Longitudinal study of aging on serum total and free testosterone levels in healthy men. J Clinl Endocrinol Metab. 2001;86:724-731.
47. Hirshkowitz M, Moore CA, O'Connor S, Bellamy M, Cunningham GR. Androgen and sleep-related erections. J Psychosom Res. 1997;42:541-546.
48. Horita H, Kumamoto Y. Study on nocturnal penile tumescence (NPT) in healthy males: study on the relationship between the serum free testosterone level and NPT. Jpn J Urol. 1994;85: 1511-1520.
49. Horwitz KB, Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. Journal of Clinical Investigation. 1982;69(4):750-758.
50. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, Snyder SH, Burnett AL. AKT-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci. 2002;99:4061-4066.
51. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fakuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun. 1990;170:843-850.
52. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effect of testosterone on sexual function in men: results of meta-analysis. Clin Endocrinol. (Oxf). 2005;63:239-243.
53. Iwakiri Y, Satoh A, Chaterjee S, Toomre DK, Chalouni CN, Fulton D, Gozmann RJ, Shah VH, Sessa WC. Proc Natl Acad Sci. 2006;103:19777-19782.
54. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83:13C-20C.
55. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3:28-36.
56. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988;36:511-519.
57. Kalinchenko SY, Koslov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6:94-99.
58. Kapoor D, Aldred H, Clarke S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care. 2007;30:911-917.
59. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-902.
60. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol. 2005;63:239-250.
61. Karadeniz T, Topsakal M, Aydogmus A, Gülgün C, Aytekin Y, Basak D. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic impotence. Urol Int. 1996;57:58-61.
62. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
63. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev. 2005;26:833-876.
64. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. Br J Urol. 2006;98(1):116-124.
65. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med. 1989;321(24):1648-1659.
66. Kumamoto Y, Yamaguchi Y, Sato Y, Suzuki R, Tanda H, Kato S, Mori K, Matsumoto H, Maki A, Kadono M, et al. Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: nocturnal penile tumescence monitoring. Hinyokika Kiyo. 1990;36(2):213-226.
67. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: a population based study. Eur J Endocrinol. 2003;149:601-608.
68. Lawless C, Cree J. Oral medications in the management of erectile dysfunction. J Am Board Family Pract. 1998;11:307-314.
69. Lazarou S, Morgentaler A. Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. Curr Urol Rep. 2005;6:476-481.
70. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab. 2004;89: 4789-4796.
71. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
72. Lugg JA, Rajfer J, González-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995;136:1495-1501.
73. Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntrop P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992a;16(12):991-997.
74. Mårin P. Krotkiewski M, Björntrop P. Androgen treatment of middle-aged obese men: effects on metabolism muscle and adipose tissues. Eur J Med. 1992b;1(6):329-336.
75. Mårin P, Oden B, Björntrop P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80:239-243.
76. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone releasing hormone agonist therapy. Int J Urol. 1999;6:19-23.
77. McCullagh EP, Renshaw JF. The effects of castration in the adult male. J Am Med Assoc. 1934;103:1140-1143.
78. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60:28-38.
79. Mersdorf A, Goldsmith PC, Diederichs W, Padula CA, Lue TF, Fishman IJ, Tanagho EA. Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J Urol. 1991;145(4):749-58.
80. Mills TM, Lewis RW, Stopper VS. Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod. 1998;59:1413-1418.
81. Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod. 1992;46(3):342-348.
82. Mittawae B, El-Nashaar AR, Fonda A, Magdy M, Shamloul R. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology. 2006;67(3):575-578.
83. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol. 2005;96:443-446.
84. Moncada S, Palmer RM, Riggs EA. Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-142.
85. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Bniganti A, Salonia A, Dehò F, Montorsi F. Common grounds for erectile dysfunction and coronary artery disease. Curr Opin Urol. 2004;14:361-365.
86. Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69-81.
87. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impotence Res. 1998;10(2):113-120.
88. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253-2263.
89. Murray FT, Wyss HU, Thomas RG, Spevack M, Glaros AG. Gonadal dysfunction in diabetic men with organic impotence. J Clin Endocrinol Metab. 1987;65:127-135.
90. National Institutes of Health. Consensus Development Panel on Impotence. Impotence. J Am Med Assoc. 1993;270:83-90.
91. Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane RJ, Goldstein I, Udelson D. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol. 1998;159(6):2229-2236.
92. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, Krane RJ, Udelson D, Saenz de Tejada I, Moreland RB. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996;156(4):1320-1329.
93. Nguyen TV, Eisman JA, Kelly PJ. Risk factors of osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255-263.
94. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J of Androl. 2005;28:125-127.
95. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women. Diabetes Care. 2002;25:55-60.
96. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM, Bremner WJ. Testosterone administration suppress adiponectin levels in men. J Androl. 2005;26:85-92.
97. Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int. 2005;95:366-370.
98. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999;83:327-333.
99. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317:599-604.
100. Phillips GB. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism. 1993;42:116-120.
101. Pirke KM, Doerr P. Age-related changes in free plasma testosterone, dihydrotestosterone and oestradiol. Acta Endocrinol (Cph). 1975;80:171-178.
102. Purifoy FE, Koopmans LH, Mayers DM. Age differences in serum androgen levels in normal adult males. Hum Biol. 1981;53:499-511.
103. Raina R, Lakin MM, Argawal A, Mascha E, Montague DK, Klein E, Zippe CD. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology. 2004;63:960-966.
104. Rebuffe-Scrive M, Mårin P, Björntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 1991; 15:791-795.
105. Reilly CM, Lewis RW, Stopper VS, Mills TM. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl. 1997;18:588-594.
106. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated (VEGF) gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impotence Res. 2003;15(1):26-37.
107. Rosenberg MT. Diagnosis and management of erectile dysfunction in the primary care setting. Int J Clin Pract. 2007;61(7):1198-1208.
108. Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav. 1988;17:87-98.
109. Santavirta S, Konttinen YT, Heliovaara M, Knekt P, Luthje P, Aromaa A. Determinations of osteoporotic thoracic vertebral fracture. Screening of 57,000 Finish women and men. Acta Orthop Scand. 1992;63:198-202.
110. Scheen A, Luyckx F, Lefebvre P. How to explore...the metabolic syndrome by its new IDF definition. Rev Med Liege. 2006;61: 48-52.
111. Schiavi RC, White D, Mandeli J, Schreiner-Engel P. Hormones and nocturnal penile tumescence in healthy aging men. Arch Sex Behav. 1993;22:207-215.
112. Seidell JC, Björntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism. 1990;39:897-901.
113. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997;15(1):21-26.
114. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658-663.
115. Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl. 2003;5(1):33-36.
116. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the telecom study. J Clin Endocrinol Metab. 1997;82:682-685.
117. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
118. Snyder PJ, Peachey H, Berlin JA, Hanmoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Homes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670-2677.
119. Sommer F, Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging. 2004;21(9):555-64.
120. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care. 2000;23:490-494.
121. Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, Hershcopf RJ, Rosenfeld RS. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab. 1988;66:1019-1023.
122. Takane KK, Husmann DA, McPhaul MJ, Wilson JD. Androgen receptor levels in the rat penis are controlled differently in distinctive cell types. Endocrinology. 1991;128(5):2234-2238.
123. Tenover JS, Matsumoto AM, Plymate RS, Brmner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987;65:1118-1126.
124. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol. 2007; 52(1):54-70.
125. Traish AM, Guay AT. Are androgens critical for penile erection in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3:382-407.
126. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, Huang YH, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl. 2003;24(3):381-7.
127. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140(4):1861-1868.
128. Traish AM, Toselli P, Jeong S-J, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl. 2005;26(2):88-94.
129. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
130. Wald M, Meacham RB, Ross LS, Niederberger CS. Testosterone replacement therapy for older men. J Androl. 2006;27:126-132.
131. Watts GF, Chew KK, Stuckey BGA. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat Clin Prac. Cardiovasc Med. 2007;4:263-273.
132. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100(16):1690-1696.
133. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J. EAU Guidelines on erectile dysfunction: an update. Eur Urol. 2006;49:806-815.
134. Wink DA, Feelish M, Fukuto J, Christodoulou D, Jourd'Heuil D, Grisham MB, Vodovotz Y, Cook JA, Krishna M, DeGraff WG, Kim S, Gamson J, Mitchell JB. The cytotoxicity of nitroxyl: possible implication for the pathophysiological role of NO. Arch of Biochem Biophys. 1998;351:66-74.
135. Xu T, Wang X, Hou S, Zhu J, Zhang X, Huang X. Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin Med J (Engl). 2002;115:1336-1340.
136. Yaman Ö, Yilmaz E, Bozlu M, Anafarta K. Alterations of intracorporeal structures in patients with erectile dysfunction. Urol Int. 2003;71:87-90.
137. Yassin A, Huebler D, Saad F. Long-acting testosterone undecanoate for parenteral testosterone therapy. Therapy. 2006a;3(6): 709-721.
138. Yassin AA, Saad F. Treatment of sexual dysfunctions in men with late onset of hypogonadism treated with testosterone only. World J Urol. 2006;24:639-644.
139. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007;4:497-501.
140. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006b;38:61-68.
141. Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008;40:259-264.
142. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med. 2006c;3:727-735.
143. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol. 2005;47(3):409-416.
144. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92(10):3844-3853.
145. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impotence Res. 1995;7(4):209-19.